Bluejay Diagnostics (BJDX) Net Income towards Common Stockholders (2020 - 2026)

Bluejay Diagnostics (BJDX) has 7 years of Net Income towards Common Stockholders data on file, last reported at -$2.0 million in Q1 2026.

• For the quarter ending Q1 2026, Net Income towards Common Stockholders fell 5.79% year-over-year to -$2.0 million; the trailing twelve-month figure through Mar 2026 stood at -$7.0 million (up 65.88% YoY), and the FY2025 full-year result was -$6.8 million, up 67.3% from the prior year.
• Net Income towards Common Stockholders fell to -$2.0 million in Q1 2026, from -$1.4 million in the prior quarter.
• In the past five years, Net Income towards Common Stockholders ranged from a high of -$1.4 million in Q4 2025 to a low of -$14.7 million in Q3 2024.
• A 5-year average of -$2.9 million and a median of -$2.3 million in 2023 frame the typical range for Net Income towards Common Stockholders.
• Across the five-year window, Net Income towards Common Stockholders plunged 791.77% in 2022 and jumped 89.14% in 2025, its largest moves.
• Tracing BJDX's Net Income towards Common Stockholders over 5 years: stood at -$2.5 million in 2022, then rose by 2.39% to -$2.4 million in 2023, then surged by 41.09% to -$1.4 million in 2024, then grew by 0.15% to -$1.4 million in 2025, then sank by 41.28% to -$2.0 million in 2026.
• Business Quant data shows BJDX's Net Income towards Common Stockholders at -$2.0 million in Q1 2026, -$1.4 million in Q4 2025, and -$1.6 million in Q3 2025.